Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease

Myeloid-derived suppressor cells (MDSC) from mice bearing bone metastases differentiate into functional osteoclasts in vitro and in vivo, through a signaling pathway that relies on nitric oxide. In addition, MDSC-targeting drugs have been shown to robustly inhibit osteolysis. Thus, MDSC stand out as...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawant, Anandi, Ponnazhagan, Selvarangan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667900/
https://www.ncbi.nlm.nih.gov/pubmed/23762794
http://dx.doi.org/10.4161/onci.24064
_version_ 1782271552589398016
author Sawant, Anandi
Ponnazhagan, Selvarangan
author_facet Sawant, Anandi
Ponnazhagan, Selvarangan
author_sort Sawant, Anandi
collection PubMed
description Myeloid-derived suppressor cells (MDSC) from mice bearing bone metastases differentiate into functional osteoclasts in vitro and in vivo, through a signaling pathway that relies on nitric oxide. In addition, MDSC-targeting drugs have been shown to robustly inhibit osteolysis. Thus, MDSC stand out as novel osteoclast progenitors and hence as candidate targets for the control of osteolytic bone disease.
format Online
Article
Text
id pubmed-3667900
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36679002013-06-12 Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease Sawant, Anandi Ponnazhagan, Selvarangan Oncoimmunology Author's View Myeloid-derived suppressor cells (MDSC) from mice bearing bone metastases differentiate into functional osteoclasts in vitro and in vivo, through a signaling pathway that relies on nitric oxide. In addition, MDSC-targeting drugs have been shown to robustly inhibit osteolysis. Thus, MDSC stand out as novel osteoclast progenitors and hence as candidate targets for the control of osteolytic bone disease. Landes Bioscience 2013-05-01 2013-05-01 /pmc/articles/PMC3667900/ /pubmed/23762794 http://dx.doi.org/10.4161/onci.24064 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Sawant, Anandi
Ponnazhagan, Selvarangan
Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease
title Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease
title_full Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease
title_fullStr Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease
title_full_unstemmed Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease
title_short Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease
title_sort myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667900/
https://www.ncbi.nlm.nih.gov/pubmed/23762794
http://dx.doi.org/10.4161/onci.24064
work_keys_str_mv AT sawantanandi myeloidderivedsuppressorcellsasanoveltargetforthecontrolofosteolyticbonedisease
AT ponnazhaganselvarangan myeloidderivedsuppressorcellsasanoveltargetforthecontrolofosteolyticbonedisease

Ejemplares similares